Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lars Fruergaard Jorgensen
Pharma
Novo's new CEO takes over at difficult time for drugmaker
Despite the challenges, Novo reported 16% overall sales growth to 154.9 billion Danish kroner (roughly $24.9 billion) in the first half of 2025.
Fraiser Kansteiner
Aug 6, 2025 11:43am
Novo's longtime CEO Lars Fruergaard Jørgensen to step down
May 16, 2025 9:41am
Novo's Wegovy takes a hit from compounders, misses estimates
May 7, 2025 9:20am
Novo reports mixed sales on GLP-1 stalwarts Ozempic, Wegovy
Nov 6, 2024 2:34pm
Novo CEO agrees to discuss potential GLP-1 price cuts with PBMs
Sep 24, 2024 5:03pm
After subpoena threat, Novo CEO Jorgensen will testify at Senate
Jun 17, 2024 11:07am
